Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by anon314on Oct 23, 2017 7:59am
277 Views
Post# 26843585

RE:The deal is costing a lot

RE:The deal is costing a lotI am never keen on dilution but let's put the dilution in perspective. According to RBC there are 707.4 million shares outstanding. Adding 54 million shares results in an increase in share count of 7.6%. For that 7.6% PLI gets access to CDN$100,000,000 in a line of credit and ~CDN$92,000,000 from the warrants.

DoesThomvest stand to do very well? Absolutely.

Do the rest of the PLI shareholders stand to gain beyond the possible/likely dilution by a 7.6% increase in shares? Absolutely.
Bullboard Posts